Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

Vogl Dan T.; Dingli David; Cornell Robert Frank; Huff Carol Ann; Jagannath Sundar; Bhutani Divaya; Zonder Jeffrey; Baz Rachid; Nooka Ajay; Richter Joshua; Cole Craig; Vij Ravi; Jakubowiak Andrzej; Abonour Rafat; Schiller Gary; Parker Terri L.; Costa Luciano J.; Kaminetzky David; Hoffman James E.; Yee Andrew J.; Chari Ajai; Siegel David; Fonseca Rafael; Van Wier Scott; Ahmann Gregory; Lopez Ilsel; Kauffman Michael; Shacham Sharon; Saint-Martin Jean-Richard; Picklesimer Carla D.; Choe-Juliak Cassandra; Stewart A. Keith

首页> 外文期刊>Journal of Clinical Oncology >Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

【24h】

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

机译：用口服胞质旋转选择抑制核导出，用于治疗复发或难治性多发性骨髓瘤

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2018年第9期|共14页
作者
Vogl Dan T.; Dingli David; Cornell Robert Frank; Huff Carol Ann; Jagannath Sundar; Bhutani Divaya; Zonder Jeffrey; Baz Rachid; Nooka Ajay; Richter Joshua; Cole Craig; Vij Ravi; Jakubowiak Andrzej; Abonour Rafat; Schiller Gary; Parker Terri L.; Costa Luciano J.; Kaminetzky David; Hoffman James E.; Yee Andrew J.; Chari Ajai; Siegel David; Fonseca Rafael; Van Wier Scott; Ahmann Gregory; Lopez Ilsel; Kauffman Michael; Shacham Sharon; Saint-Martin Jean-Richard; Picklesimer Carla D.; Choe-Juliak Cassandra; Stewart A. Keith;
展开▼
作者单位

Univ Penn Perelman Sch Med Abramson Canc Ctr 12th Floor South Pavil Off 12-176 Philadelphia PA;

Mayo Clin Rochester MN USA;

Vanderbilt Univ Med Ctr Nashville TN USA;

Johns Hopkins Univ Baltimore MD USA;

Mt Sinai Sch Med Tisch Canc Inst New York NY USA;

Wayne State Univ Karmanos Canc Inst Detroit MI USA;

Wayne State Univ Karmanos Canc Inst Detroit MI USA;

H Lee Moffitt Canc Ctr &

Res Inst Tampa FL USA;

Emory Univ Winship Canc Inst Atlanta GA 30322 USA;

Hackensack Univ Med Ctr John Theurer Canc Ctr Hackensack NJ USA;

Univ Michigan Ann Arbor MI 48109 USA;

Washington Univ Sch Med St Louis MO USA;

Univ Chicago Med Ctr Chicago IL 60637 USA;

Indiana Univ Ctr Canc Indianapolis IN 46204 USA;

Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;

Yale Sch Med New Haven CT USA;

Univ Alabama Birmingham Birmingham AL USA;

NYU Langone Med Ctr New York NY USA;

Univ Miami Sylvester Canc Ctr Miami FL USA;

Massachusetts Gen Hosp Ctr Canc Boston MA USA;

Icahn Sch Med Mt Sanai New York NY USA;

Hackensack Univ Med Ctr John Theurer Canc Ctr Hackensack NJ USA;

Mayo Clin Arizona Phoenix AZ USA;

Mayo Clin Arizona Phoenix AZ USA;

Mayo Clin Arizona Phoenix AZ USA;

Mayo Clin Arizona Phoenix AZ USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Karyopharm Therapeut Newton MA USA;

Mayo Clin Arizona Phoenix AZ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma [J] . Vogl Dan T., Dingli David, Cornell Robert Frank, Journal of Clinical Oncology . 2018,第9期

机译：用口服胞质旋转选择抑制核导出，用于治疗复发或难治性多发性骨髓瘤
2. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia [J] . Alexander Thomas B., Lacayo Norman J., Choi John K., Journal of Clinical Oncology . 2016,第34期

机译：Selinexor，一种核出口的选择性抑制剂，与氟达拉滨和阿糖胞苷合用，在小儿复发或难治性急性白血病中进行一期研究
3. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia [J] . Alexander Thomas B., Lacayo Norman J., Choi John K., Journal of Clinical Oncology . 2016,第34期

机译：I阶段研究Selinexor，核导出选择性抑制剂，与氟赤虫和糖碱相结合，在儿科复发或难治性急性白血病中
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma [O] . Dan T. Vogl, David Dingli, Robert Frank Cornell, -1

机译：口服Selinexor选择性抑制核输出治疗复发性或难治性多发性骨髓瘤
7. Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia [O] . Thomas B. Alexander, Norman J. Lacayo, John K. Choi, 2016

机译：I阶段研究Selinexor，核导出选择性抑制剂，与氟赤虫和糖碱相结合，在儿科复发或难治性急性白血病中

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

摘要

著录项

相似文献

相关主题

期刊订阅